MIAMI, April 11, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced the appointment of Robert H. Getzenberg, Ph.D., as Executive Vice President of Clinical Development.
Dr. Getzenberg will lead the clinical development of Veru’s portfolio of drugs under development, including Tamsulosin DRS (Tamsulosin HCl extended release for oral suspension) for the treatment of benign prostatic hyperplasia (BPH), MSS-722 for male infertility, APP-944 for hot flashes in men who are on hormonal therapies for advanced prostate cancer, and APP-111 for prostate, ovarian and breast cancers.
“Robert is eminently qualified to lead our product development efforts,” said Mitchell Steiner, M.D., President and Chief Executive Officer of The Female Health Company / Veru Healthcare. “He is a highly regarded pharmaceutical executive who also has made significant contributions as a scientific researcher, investigator and tenured professor in the worlds of urology, oncology and pharmacology. Notably, he brings expertise in drug development for the treatment of BPH and prostate cancer.”
Dr. Getzenberg, most recently served as Therapeutic Area Lead, Prostate Cancer for GTx, Inc., where he was responsible for advancing the company’s pipeline in prostate cancer, as well as supporting efforts in Stress Urinary Incontinence (SUI) and breast cancer. He previously spent 18 years as a faculty member of the Johns Hopkins University School of Medicine and the University of Pittsburgh School of Medicine. At Johns Hopkins, Dr. Getzenberg served as co-director of the Prostate Cancer Program in addition to his role as director of research for the Brady Urological Institute and professor for the departments of urology, oncology and pharmacology & molecular sciences. At the University of Pittsburgh, he was director of research and co-director of the Prostate and Urologic Cancer Center and professor in the departments of pathology, medicine, pharmacology and urology. Dr. Getzenberg is the recipient of a number of awards including the 2000 University of Pittsburgh Chancellor’s Distinguished Research Award and was selected as one of the “40 under 40” by Pittsburgh Magazine. Dr. Getzenberg has given numerous international lectures related to his work, including the first Donald Gleason Lecture at the University of Minnesota in 2012 and the Weisbach Lecture at the University of Michigan in 2007. He has been the keynote speaker at urology and oncology meetings in Japan, China and throughout Europe. Dr. Getzenberg has and continues to serve in many leadership positions in urology research, including as President of the Society of Basic Urologic Research. Dr. Getzenberg has authored or co-authored more than 165 peer-reviewed journal articles, book chapters and reviews, and is an inventor on six awarded or pending patents.
Dr. Getzenberg completed his postdoctoral fellowship at the Yale University School of Medicine. He earned a Ph.D. degree in biochemistry, cellular & molecular biology from the Johns Hopkins University School of Medicine and a bachelor of arts degree, with high honors, in microbiology from Rutgers College, Rutgers University.
About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway. The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:
- Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom® in the consumer health products sector and PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
- The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business. This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.
More information about the Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org. For corporate and investor-related information about the Company, please visit https://veruhealthcare.com/investors.